EUROEYES (01846) has announced that on February 20, 2026 (after trading hours), its wholly-owned subsidiary, EuroEyes Netherlands, entered into an agreement to acquire all issued shares of FYEO Europe B.V. from Committed Capital, STAK Batoan, Mateflo, FYEO WPP, and STAK FYEO. The total consideration will be calculated as the equity consideration plus locked-box compensation, minus any leakage amount. Assuming the completion date is July 15, 2026, and the leakage amount is zero, the maximum estimated cost is approximately €145.8 million (equivalent to approximately HK$1.234 billion). The company has applied to the Stock Exchange for the resumption of trading of its shares, effective at 9:00 a.m. on February 27, 2026. The target company is primarily engaged in refractive surgery via laser treatments or lens implantation. The target group is a leading private refractive surgery platform in the Dutch market, specializing in lens implantation and laser eye surgeries, including Refractive Lens Exchange (RLE), Implantable Lens (IL) procedures, SMILE, Intralasik, TransPRK, and Lasek. Given the target group's leading position in the rapidly growing Dutch market, the Board of Directors believes the acquisition represents an excellent strategic fit. The rationale is the high compatibility between the company and the target group, as both are pure-play refractive surgery providers with a fully patient-centric approach. The Board also considered that the target group is well-positioned to continue its growth trajectory, supported by several favorable growth drivers, including an expanding directly accessible end-market and technological advancements in refractive surgery. The acquisition is expected to significantly strengthen the group's market position, enhance overall competitiveness, ensure long-term sustainable development, and create value for the company and its shareholders.